A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

October 16, 2023

Study Completion Date

October 16, 2023

Conditions
Transthyretin Amyloid Cardiomyopathy
Interventions
DRUG

Tafamidis

61 mg, once daily, oral administration, for 12 months.

Trial Locations (9)

100034

Peking University First Hospital, Beijing

100191

Peking University Third Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

116014

The First Affiliated Hospital of Dalian Medical University, Dalian

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

410011

The Second Xiangya Hospital of Central South University, Changsha

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan

610041

West China Hospital of Sichuan University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY